Imbrium Therapeutics Completes Final Patient Visit in Overactive Bladder Trial

Imbrium Therapeutics L.P., a subsidiary of Purdue Pharma L.P., has successfully reached the milestone of the last patient’s last visit in its Phase 1b clinical trial assessing the investigational drug sunobinop for overactive bladder syndrome (OAB).

Sunobinop is an innovative, potential first-in-class oral medication developed by Imbrium Therapeutics. It works by targeting and activating the nociceptin/orphanin-FQ peptide receptor (NOP), a protein prevalent in both the central and peripheral nervous systems. This receptor is implicated in numerous biological functions, including bladder regulation.

The Phase 1b study was a multicenter, randomized, double-blind, placebo-controlled crossover trial involving 51 female patients diagnosed with OAB. The primary aim was to evaluate the effects of administering sunobinop at bedtime on critical symptoms of OAB, such as urinary urgency, frequency, incontinence, and nocturia, in comparison to a placebo. Overactive bladder is a chronic condition that significantly diminishes patients' quality of life and affects approximately 14% of the U.S. adult population.

Dr. Julie Ducharme, Vice President and Chief Scientific Officer, emphasized the importance of developing new treatment options for the millions suffering from the disruptive symptoms of OAB. She stated, "This study will help us learn more about sunobinop's potential to be a new treatment option." She further mentioned that results from the study are anticipated to be reviewed and analyzed later in the year.

Craig Landau, MD, President and CEO of Purdue Pharma, expressed satisfaction with the progress, noting, "We are pleased to achieve last patient last visit in the sunobinop Phase 1b study. Our continued progress in this work demonstrates our ongoing commitment to innovation through research and development."

Beyond overactive bladder syndrome, Imbrium Therapeutics is also exploring the potential of sunobinop as a treatment for interstitial cystitis/bladder pain syndrome (IC/BPS) and separately for alcohol use disorder.

Imbrium Therapeutics L.P. is a clinical-stage biopharmaceutical company that focuses on advancing medical science through the development of new therapeutics. The company targets a broad range of medical conditions, including genitourinary disorders, central nervous system disorders, oncology, and non-opioid pain management. As a subsidiary of Purdue Pharma L.P., Imbrium is committed to addressing unmet medical needs through a diversified pipeline of investigational drugs and collaborative efforts with industry and academic partners.